Patents by Inventor David Meyre

David Meyre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENPP1 (PC-1) GENE HAPLOTYPE ASSOCIATED WITH THE RISK OF OBESITY AND TYPE 2 DIABETES AND THEIR APPLICATIONS
    Publication number: 20120009592
    Abstract: The present invention is directed to a method for determining if a subject is at increased risk to develop obesity or pathology related to obesity by determining the presence of a haplotype comprising three specific SNPs in a DNA or RNA sample of this subject and/or an elevated serum ENPP1 protein concentration. The present invention also relates to a kit and to an isolated nucleic sequence, vector or recombinant cell comprises said ENPP1 gene haplotype. The invention further comprises a method for selecting a compound for the treatment or the prevention of obesity or pathology related to obesity and a method for determining the efficacy of a drug to reduce the risk of obesity or pathology related to obesity in a patient.
    Type: Application
    Filed: August 3, 2011
    Publication date: January 12, 2012
    Applicants: Universite de Droit de la La Sante de Lille 2, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Philippe Froguel, David Meyre, Christian Dina, Philippe Boutin
  • ENPP1 (PC-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications
    Patent number: 8017324
    Abstract: The present invention is directed to a method for determining if a subject is at increased risk to develop obesity or pathology related to obesity by determining the presence of a haplotype comprising three specific SNPs in a DNA or RNA sample of this subject and/or an elevated serum ENPP1 protein concentration. The present invention also relates to a kit and to an isolated nucleic sequence, vector or recombinant cell comprises said ENPP1 gene haplotype. The invention further comprises a method for selecting a compound for the treatment or the prevention of obesity or pathology related to obesity and a method for determining the efficacy of a drug to reduce the risk of obesity or pathology related to obesity in a patient.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: September 13, 2011
    Assignees: Centre National de la Recherche Scientifique, Universite de Droit de la La Sante de Lille 2
    Inventors: Philippe Froguel, David Meyre, Christian Dina, Philippe Boutin